Register for free to listen to this article
Listen with Speechify
0:00
1:00
REHOVOT, Israel—Proteologics Inc. recently announced that it has been granted U.S. Patent No. 7,268,227 relating to its leading antiviral program. This patent broadly covers siRNA molecules that can inhibit the expression of Proteologics' antiviral drug target, hPOSH, a human protein that was characterized by Proteologics as a ubiquitin ligase essential for HIV biogenesis. Proteologics has antiviral drug discovery programs based on proprietary research of host-protein ubiquitin-ligase drug targets shown to be essential for the HIV life cycle. Proteologics' strategy is to target human pathways evolutionarily required for viral biogenesis to prevent completion of the viral life cycle in human cells. This new approach allows Proteologics to develop drugs that have not been previously encountered by viruses and may be more effective than current therapies against the emergence of viral resistance. 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

An illustration of three immune cells attacking a cancer cell, representing the mechanism of chimeric antigen receptor-based cell therapy

Cell therapy's next frontiers

As cell therapy evolves rapidly, what advancements are on the horizon? 
An illustration of a human heart on top of a DNA strand

Reversing rejection: gene therapy in modern transplantation

Emerging gene editing approaches pave the way for safer, more successful transplants.
An 3D illustration of protein molecules in different colors

Identifying druggable therapeutic targets

Effective target identification is central to drug discovery, but finding the right drug target is not as simple as it may seem in theory. 
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue